The rise of transcutaneous drug delivery for the management of alopecia: a review of existing literature and an eye towards the future

References

• Severie G, Sinclair R, Jl H, Dr E, Mr M. Androgenetic alopecia in men aged 40–69 years: prevalence and risk factors. Br J Dermatol. 2003 Dec;149(6):1207–13.
   PubMed Web of Science ®Google Scholar
• Shankar DK, Chakravarthi M, Shipakar R. Male androgenetic alopecia: population-based study in 1,005 subjects. Int J Tricology. 2009 Jul;1(2):131–33.
   PubMedGoogle Scholar
• Birch MP, Messenger JF, Messenger AG. Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol. 2001 Feb;144(2):297–304.
   PubMed Web of Science ®Google Scholar
• Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359–65.
   PubMed Web of Science ®Google Scholar
• Mirzoyev SA, Schrum AG, Davis MDP, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009. J Invest Dermatol. 2014 Apr;134(4):1141–42.
   PubMed Web of Science ®Google Scholar
• Bilgic O, Bilgic A, Bahali K, Gurkan A, Yilmaz A. Psychiatric symptomatology and health-related quality of life in children and adolescents with alopecia areata. J Eur Acad Dermatol Venereol. 2013 Nov;28(11):1463–68.
   PubMed Web of Science ®Google Scholar
• Christensen T, Yang JS, Bullying C-SL. Quality of life in pediatric alopecia areata. Skin Appendage Disord. 2017 3 Mar;(3):115–18.
   PubMed Web of Science ®Google Scholar
• Dubois M, Baumstarck-Barrau K, Gaudy-Marqueste C, Richard MA, Loundou A. Quality of life in alopecia areata: A study of 60 cases. J Invest Dermatol. 2010 Aug;130(19):2830–33.
   PubMedGoogle Scholar
• Cash TF. The psychosocial consequences of androgenetic alopecia: a review of the research literature. Br J Dermatol. 1999 Sept;141(3):398–405.
   PubMed Web of Science ®Google Scholar
• Baghestani S, Zare S, Seddigh SH. Severity of depression and anxiety in patients with alopecia areata in Bandar Abbas, Iran. Dermatology Reports. 2015 Dec;7(3):6063.
   PubMed Web of Science ®Google Scholar
• Hordinsky MK. Current treatments for alopecia areata. J Invest Dermatol Symp Proc. 2015 Nov;17(2):44–46.
   PubMedGoogle Scholar
• Xing L, Zhenpeng D, Jabbari A, Cerise JE, Higgins CA. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nature Medicine. 2014 Aug;20(9):1043–49.
   PubMed Web of Science ®Google Scholar
• Chang KH, Rojhirunsakool S, Goldberg LJ. Treatment of severe alopecia areata with intralesional steroid injections. J Drugs Dermatol. 2009 Oct;8(10):909–12.
   PubMed Web of Science ®Google Scholar
• Park HS, Kim MW, Lee JS, Yoon HS, Huh CH. Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: A case series. J Amer Acad Dermatol. 2017 Nov;77(5):978–80.
   PubMed Web of Science ®Google Scholar
• Ea O, Ag M, Shapiro J, Wf B, Mk H, Jl R, Stough D, Washenik K, Da W. Evaluation and treatment of male and female pattern hair loss. J Amer Acad Dermatol. 2005 Feb;52(2):301–11.
   PubMed Web of Science ®Google Scholar
• Leiros GJ, Attorresi AI, Balana ME. Hair follicle stem cell differentiation is inhibited throughcross-talk between Wnt⁄b-catenin and androgen signaling in dermal papilla cells from patients with androgenetic alopecia. Br J Dermatol. 2012Apr;166(5):1035–42.
   PubMed Web of Science ®Google Scholar
• Savin RC. Use of topical minoxidil in the treatment of male pattern baldness. J Am Acad Dermatol. 1987 Mar;16(3):696–704.
   PubMed Web of Science ®Google Scholar
• Kaufman KD, Olsen EA, Whiting D, Price VH, Van Neste D. Finasteride in the treatment of men with androgenetic alopecia. J Amer Acad Dermatol. 1998 Oct;39(4):578–89.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Weiner MS. Topical minoxidil in male pattern baldness: effects of discontinuation of treatment. J Am Acad Dermatol. 1987 Jul;17(1):97–101.
   PubMed Web of Science ®Google Scholar
• Henry S, McAllister DV, Allen MG, Prausnitz MR. Microfabricated microneedles: a novel approach to transdermal drug delivery. J Pharm Sci. 1998 Aug;87(8):922–25.
   PubMed Web of Science ®Google Scholar
• Williams ML, Elias PM. The extracellular matrix of stratum corneum: role of lipids in normal and pathological function. Crit Rev Ther Drug Carrier Syst. 1987;3(2):95–122.
   PubMed Web of Science ®Google Scholar
• Potts RO, Francouer ML. The influence of stratum corneum morphology on water permeability. J Invest Dermatol. 1991 Apr;96(4):495–99.
   PubMed Web of Science ®Google Scholar
• Prausnitz MR, Elias PM, Franz TJ, Schmuth M, Tsai JC, Menon GK, Holleran WM, Feingold KR. Skin barrier and transdermal drug delivery. Bolognia JL, Jorizzo JL, Schaffer JV. editors. Dermatology, 3rd. Philadelphia, PA:Elsevier Saunders;2012. 2065–74.
   Google Scholar
• Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR. Fractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg Med. 2004;34(5):426–38.
   PubMed Web of Science ®Google Scholar
• Hantash BM, Bedi VP, Chan KF, Zachary CB. Ex vivo histological characterization of a novel ablative fractional resurfacing device. Lasers Surg Med. 2007;39(2):87–95.
   PubMed Web of Science ®Google Scholar
• Sklar LR, Burnett CT, Waibel JS, Moy RL, Ozog DM. Laser assisted drug delivery: a review of an evolving technology. Lasers Surg Med. 2014 Apr;46(4):249–62.
   PubMed Web of Science ®Google Scholar
• Kim WS, Lee HI, Lee JW, Lim YY, Lee SJ, Kim BJ, Kim MN, Song KY, Park WS. Fractional photothermolysis laser treatment of male pattern hair loss. Dermatol Surg. 2011 Jan;37:41–51.
   PubMed Web of Science ®Google Scholar
• Lee GY, Lee SJ, Kim WS. The effect of a 1550 nm fractional erbium–glass laser in female pattern hair loss. J Eur Acad Dermatol Venereol. 2011 Dec;25(12):1450–54.
   PubMed Web of Science ®Google Scholar
• Cho S, Choi MJ, Zheng Z, Goo B, Kim DY, Cho SB. Clinical effects of non-ablative and ablative fractional lasers on various hair disorders: a case series of 17 patients. J Cosmet Laser Ther. 2013 Apr;15(2):74–79.doi: 10.3109/14764172.2013.764436. Epub 2013 Mar 6
   PubMed Web of Science ®Google Scholar
• Yalici-Armagan B, Elcin G. The effect of neodymium: yttrium aluminum garnet and fractional carbon dioxide lasers on alopecia areata: a prospective controlled clinical trial. Dermatol Surg. 2016 Apr;42(4):500–06. doi:10.1097/DSS.0000000000000649.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhuo F, Li L. Enhancing hair growth in male androgenetic alopecia by a combination of fractional CO2 laser therapy and hair growth factors. Lasers Med Sci. 2017 Nov;32(8):1711–18.
   PubMed Web of Science ®Google Scholar
• Ak J, Uk U, Pk R, Akj A, Rkp C. Original article: platelet-rich plasma with microneedling in androgenetic alopecia along with dermoscopic pre- and post-treatment evaluation. J Cosmet Dermatol. 2017 Aug. doi: 10.1111/jocd.12394. ePub ahead of print
   Web of Science ®Google Scholar
• Shah KB, Shah AN, Solanki RB, Raval RC A comparative study of microneedling with platelet-rich plasma plus topical minoxidil (5%) and topical minoxidil (5%) alone in androgenetic alopecia. Int J Trichology. 2017 Jan;9(1):14–18.
   PubMedGoogle Scholar
• Ito T, Yoshimasu T, Furukawa F, Nakamura M, Tokura Y. Three-microneedle device as an effective option for intralesional corticosteroid administration for the treatment of alopecia areata. J Dermatol. 2017 Nov;44(11):e304–05.
   PubMed Web of Science ®Google Scholar
• Lee YB, Eun YS, Lee JH, Cheon MS, Park YG. Effects of topical application of growth factors followed by microneedle therapy in women with female pattern hair loss: a pilot study. J Dermatol. 2013 Jan;40(1):81–83.
   PubMed Web of Science ®Google Scholar
• Farid CC, Abdelmaksoud RA. Platelet-rich plasma microneedling versus 5% topical minoxidil in the treatment of patterned hair loss. Journal of the Egyptian Women’s Dermatologic Society. 2016 Jan;13(1):29–36.
   Google Scholar
• El-Fakahany H, Ha R, Medhat W. Using automated microneedling with platelet rich plasma for treating cicatricial alopecia, recalcitrant alopecia areata and traction alopecia, case report. J Amer Acad Dermatol. 2016 May;74(5):AB140.
   Web of Science ®Google Scholar
• Kaur A, Yadav S, Kumaran S. Platelet rich plasma: A novel therapeutic perspective for female pattern alopecia. 95th Annual Meeting of the British Association of Dermatologists. Conference Publication. 2015 Jul;173:100.
   Google Scholar
• Ro BO, Son HO, Lee SY, Chun SW. Comparison of therapeutic effect of systematic growth factor microneedle treatment in the patients with male pattern hair loss by varying depth of absorption. 3rd Eastern Asia Dermatology Congress. Conference Publication. 2014Oct;41:21.
   Google Scholar
• Dhurat R, Mathapati S. Response to microneedling treatment in men with androgenetic alopecia who failed to respond to conventional therapy. Indian J Dermatol. 2015 May-Jun;60(3):260–63. doi:10.4103/0019-5154.156361.
   PubMed Web of Science ®Google Scholar
• Yoo KH, Lee JW, Li K, Kim BJ, Kim MN. Photodynamic therapy with methyl 5-aminolevulinate acid might be ineffective in recalcitrant alopecia totalis regardless of using a microneedle roller to increase skin penetration. Dermatol Surg. 2010 May;36(5):618–22.doi: 10.1111/j.1524-4725.2010.01515.x. Epub 2010 Apr 2
   PubMed Web of Science ®Google Scholar
• Dhurat R, Sukesh M, Avhad G, Dandale A, Pal A, Pund P. A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. Int J Trichology. 2013 Jan;5(1):6–11. doi:10.4103/0974-7753.114700.
   PubMedGoogle Scholar
• Issa MC, Pires M, Silveira P, Xavier de Brito E, Sasajima C. Transepidermal drug delivery: a new treatment option for areata alopecia? J Cosmet Laser Ther. 2015 Feb;17(1):37–40.doi: 10.3109/14764172.2014.967778. Epub 2014 Oct 16
   PubMed Web of Science ®Google Scholar
• Chandrashekar B, Yepuri V, Mysore V. Alopecia areata-successful outcome with microneedling and triamcinolone acetonide. J Cutan Aesthet Surg. 2014 Jan;7(1):63–64. doi:10.4103/0974-2077.129989.
   PubMedGoogle Scholar
• Lee JW, Yoo KH, Kim BJ, Kim MN. Photodynamic therapy with methyl 5-aminolevulinate acid combined with microneedle treatment in patients with extensive alopecia areata. Clin Exp Dermatol. 2010 Jul;35(5):548–49.doi: 10.1111/j.1365-2230.2009.03695.x. Epub 2009 Nov 3
   PubMed Web of Science ®Google Scholar
• Bao L, Gong L, Guo M, Liu T, Shi A. Randomized trial of electrodynamic microneedle combined with 5% minoxidil topical solution for the treatment of Chinese male Androgenetic alopecia. J Cosmet Laser Ther. 2017 Oct. ePub ahead of print doi: 10.1080/14764172.2017.1376094.
   PubMedGoogle Scholar
• Harris AG, Murrel DF Combining microneedling and triamcinolone-a novel way to increase the tolerability of intralesional corticosteroid delivery in children with alopecia areata. 48th Annual Scientific Meeting of the Australasian College of Dermatologists, Conference Publication;56:40–41.
   Google Scholar
• Marques E, Almeida F, Almeida L, Queiroz R, Padua J A 48 month clinical follow up of female and male pattern hair loss treatment with a one month fractional laser and transepidermal drug delivery session in 100 Brazilian patients. 36th Annual Conference of the American Society for Laser Medicine and Surgery, Conference Publication, 2016 Mar;48:7–8.
   Google Scholar
• Avram MM, Tope WD, Yu T, Szachowicz E, Nelson JS. Hypertrophic scarring of the neck following ablative fractional carbon dioxide laser resurfacing. Lasers Surg Med. 2009 Mar;41(3):185–88.
   PubMed Web of Science ®Google Scholar
• Pahwa M, Pahwa P, Zaheer A. “Tram Track Effect” after treatment of acne scars using a microneedling device. Dermatologic Surgery. 2012 Jul;38(7):1107–08.
   PubMed Web of Science ®Google Scholar